J. Anthony Ware Sells 3,900 Shares of AnaptysBio (NASDAQ:ANAB) Stock

by · The Markets Daily

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director J. Anthony Ware sold 3,900 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $49.58, for a total value of $193,362.00. Following the transaction, the director owned 9,630 shares of the company’s stock, valued at approximately $477,455.40. This represents a 28.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

AnaptysBio Price Performance

Shares of ANAB stock traded down $0.29 on Tuesday, hitting $50.04. The stock had a trading volume of 406,939 shares, compared to its average volume of 692,903. The company’s 50 day moving average price is $39.15 and its 200-day moving average price is $29.22. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $51.43. The firm has a market capitalization of $1.39 billion, a P/E ratio of -17.74 and a beta of 0.28.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, equities analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has authorized a stock repurchase program on Friday, November 21st that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANAB. First Light Asset Management LLC raised its position in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Palo Alto Investors LP boosted its holdings in AnaptysBio by 20.9% in the first quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock valued at $18,975,000 after purchasing an additional 176,742 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in AnaptysBio by 4,852.7% in the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after purchasing an additional 822,975 shares during the last quarter. Woodline Partners LP raised its holdings in AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. Finally, 683 Capital Management LLC lifted its position in shares of AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after buying an additional 304,373 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Barclays decreased their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Wells Fargo & Company boosted their price objective on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, HC Wainwright cut their target price on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.40.

Read Our Latest Stock Report on AnaptysBio

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Read More